Warwick spinout to revolutionise AI for cellular pathology

A longstanding research collaboration between the University of Warwick and University Hospitals Coventry and Warwickshire has led to the development of exciting new technology which will speed up the diagnoses of cancer and improve treatment for cancer patients.

Using artificial intelligence, the technology will analyse tissue samples from people with suspected cancer and accelerate diagnosis by functioning even when the pathologist is unavailable. The pioneering technology will enable automatic screening of normal samples so that pathologists can better use their resources and focus on those that show signs of cancer.

The scientific team of Prof Nasir Rajpoot and Dr Simon Graham (Department of Computer Science, University of Warwick) and Prof David Snead (consultant pathologist at University Hospital Coventry and Warwickshire) have been working with Warwick Innovations (University of Warwick) to form a spinout company, Histofy Ltd, that will further develop the technology into software that can be used in cancer labs throughout the world.

Tim Francis, Business Development Manager – Warwick Innovations said: “This is an important step in the realisation of technology developed through the research partnership between Warwick and UHCW. There is great potential for improvements in cancer treatment and patient outcomes.”

An Important Milestone

Birmingham, UK (2023.03.08) – Histofy, a medical technology company specialising in developing transparent AI models for pathology, has announced that it is now a spinout from the University of Warwick. The company’s technology aims to revolutionise tissue based research and practice by bringing AI technologies for deep tissue profiling to the market.

Histofy’s innovative technology brings avant-garde AI to histopathology and offers precise and accurate tissue profiling that will enable faster and more accurate diagnostics, prognostics and predictive analytics. With a focus on the clinical and biopharma markets, the company’s technology has the potential to improve patient outcomes and reduce healthcare costs.

The spinout from the University of Warwick marks an important milestone for Histofy, as it enables the company to develop and commercialise its innovative technology. The founding team of medical and AI experts is dedicated to driving innovation in the pathology field through the use of transparent AI models.